Saturday 17 October 2026
Export ANIP’s income statement to Excel — free account
ANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
72.08
0.20
−0.28%
Follow ANIP
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
175.06 | 0.00 | 34.11 | 120.92 | 0.00 | 0.00 | 0.00 | 66.50 | 0.00 | 22.55 |
Piotroski F-Score |
5 | 4 | 6 | 5 | 3 | 3 | 5 | 8 | 2 | 7 |
P/S ratio |
5.45 | 4.49 | 2.61 | 3.54 | 1.67 | 2.69 | 2.06 | 2.11 | 1.74 | 1.79 |
Altman Z-Score |
3.57 | 2.79 | 2.09 | 2.75 | 1.35 | 1.23 | 1.40 | 2.42 | 1.43 | 2.30 |
P/FCF ratio |
0.00 | 0.00 | 9.36 | 40.38 | 0.00 | 0.00 | 0.00 | 10.25 | 18.39 | 10.49 |
Altman Z″-Score (non-manufacturers) |
2.99 | 2.67 | 1.33 | 3.09 | 1.81 | 2.36 | 2.23 | 3.85 | 1.98 | 3.26 |
Beneish M-Score |
(1.36) | (2.64) | (3.06) | (2.91) | (2.47) | (2.42) | (2.36) | (2.95) | (2.41) | (2.62) |
P/Operating CF |
58.04 | 50.21 | 19.30 | 152.04 | (60.86) | (47.63) | (147.97) | 23.01 | 67.33 | 52.13 |
P/B ratio |
4.13 | 4.54 | 2.67 | 3.43 | 1.78 | 1.74 | 2.08 | 2.38 | 2.65 | 2.93 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 25.34 | 96.27 | 48.86 | 19.24 | 5.27 | 0.00 | 0.00 |
EV/Sales |
6.18 | 5.45 | 2.74 | 4.13 | 2.52 | 3.55 | 2.80 | 2.25 | 2.51 | 2.16 |
EV/EBITDA |
18.73 | 17.14 | 8.01 | 14.00 | 18.35 | 102.90 | 36.29 | 10.25 | 18.81 | 9.41 |
EV/Operating CF |
28.92 | 24.45 | 8.25 | 18.71 | 34.40 | 231.03 | (28.34) | 9.20 | 24.07 | 10.29 |
EV/FCF |
(6.53) | (14.06) | 9.85 | 47.21 | (9.90) | (43.44) | (18.85) | 10.89 | 26.53 | 12.63 |
Quick Ratio |
2.29 | 2.29 | 0.65 | 2.18 | 1.32 | 2.61 | 2.20 | 2.63 | 1.92 | 2.07 |
Current Ratio |
3.22 | 3.35 | 0.92 | 3.04 | 2.17 | 3.68 | 3.46 | 3.57 | 2.72 | 2.71 |
Net Debt/EBITDA |
2.20 | 3.03 | 0.40 | 2.02 | 6.21 | 25.08 | 9.57 | 0.60 | 5.77 | 1.59 |
Debt/Assets |
37.37% | 48.89% | 16.38% | 40.66% | 40.26% | 37.24% | 37.70% | 31.59% | 48.59% | 42.84% |
Debt/Equity |
0.71 | 1.15 | 0.36 | 0.87 | 0.95 | 0.80 | 0.85 | 0.62 | 1.46 | 1.14 |
Asset Turnover |
0.42 | 0.48 | 0.48 | 0.47 | 0.45 | 0.35 | 0.41 | 0.58 | 0.56 | 0.65 |
Operating CF/Net income |
7.02 | (36.63) | 4.37 | 7.49 | (0.68) | (0.08) | 0.63 | 6.93 | (3.18) | 2.40 |
Capex/Depreciation |
(6.67) | (3.87) | (0.32) | (0.62) | (1.53) | (0.44) | (0.26) | (0.31) | (0.04) | (0.38) |
Interest Coverage |
1.77 | 2.35 | 2.40 | 1.26 | (1.69) | (3.34) | (1.26) | 1.74 | 0.03 | 5.54 |
| 2.37% | (0.62%) | 8.25% | 2.97% | (11.04%) | (16.16%) | (15.29%) | 4.60% | (4.82%) | 16.34% | |
| 1.29% | (0.29%) | 3.64% | 1.37% | (4.91%) | (6.94%) | (6.47%) | 2.06% | (1.84%) | 5.66% | |
ROIC |
4.77% | 5.13% | 9.83% | 3.04% | (2.68%) | (4.56%) | (3.86%) | 5.62% | 0.04% | 8.05% |
Return on Tangible Assets |
4.77% | (0.95%) | 60.35% | 3.66% | (16.95%) | (14.92%) | (17.19%) | 4.09% | (5.15%) | 14.36% |
Average Days of Receivables |
130.24 | 121.34 | 117.41 | 127.46 | 167.72 | 217.05 | 190.86 | 121.52 | 131.73 | 116.14 |
Research and Development Expense of Revenue |
2.26% | 5.13% | 7.63% | 9.59% | 7.68% | 5.26% | 7.05% | 7.04% | 7.26% | 5.85% |
Selling, General and Administrative Expense of Revenue |
21.64% | 17.86% | 21.86% | 27.04% | 31.17% | 39.00% | 39.21% | 33.22% | 40.63% | 35.97% |
Intangible Assets out of Total Assets |
0.55 | 0.56 | 0.48 | 0.40 | 0.42 | 0.42 | 0.37 | 0.26 | 0.47 | 0.38 |
Share Based Compensation of Revenue |
4.72% | 3.44% | 3.36% | 4.46% | 6.21% | 4.85% | 4.61% | 4.24% | 4.78% | 4.29% |
Graham Net Nets |
(0.07) | (0.13) | (0.15) | (0.08) | (0.27) | (0.16) | (0.12) | 0.07 | (0.31) | (0.09) |
Graham Number |
10.80 | 0.00 | 22.40 | 14.36 | 0.00 | 0.00 | 0.00 | 21.57 | 0.00 | 46.08 |
Earnings Yield |
0.57% | (0.13%) | 2.93% | 0.83% | (6.47%) | (7.06%) | (7.59%) | 1.50% | (2.03%) | 4.43% |
Free Cash Flow Yield |
(17.34%) | (8.64%) | 10.68% | 2.48% | (15.27%) | (3.04%) | (7.20%) | 9.76% | 5.44% | 9.53% |
Revenue per Share |
11.24 | 15.32 | 17.26 | 17.44 | 17.43 | 17.16 | 19.46 | 27.04 | 31.80 | 44.05 |
Operating CF per Share |
2.40 | 3.41 | 5.74 | 3.85 | 1.28 | 0.26 | (1.92) | 6.61 | 3.31 | 9.24 |
Capex per Share |
(13.02) | (9.35) | (0.93) | (2.33) | (5.71) | (1.67) | (0.97) | (1.03) | (0.18) | (1.71) |
Free Cash Flow per Share |
(10.62) | (5.94) | 4.81 | 1.53 | (4.43) | (1.40) | (2.88) | 5.58 | 3.14 | 7.53 |
Cash per Share |
2.39 | 2.70 | 3.68 | 5.26 | 0.66 | 7.96 | 3.27 | 12.28 | 7.83 | 14.70 |
Shareholders Equity per Share |
14.82 | 15.13 | 16.89 | 17.97 | 16.36 | 28.48 | 20.82 | 25.42 | 22.18 | 26.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.82 | 15.13 | 16.89 | 17.97 | 16.36 | 28.48 | 20.82 | 25.42 | 22.18 | 26.96 |
Free Cash Flow |
(121.59) | (68.57) | 56.16 | 18.08 | (53.05) | (17.67) | (46.91) | 100.45 | 60.58 | 150.90 |
Working Capital |
71.06 | 92.38 | (12.67) | 126.02 | 91.76 | 234.24 | 244.82 | 374.34 | 334.00 | 475.01 |
Capital Expenditures |
(149.06) | (107.99) | (10.91) | (27.55) | (68.32) | (20.99) | (15.70) | (18.51) | (3.44) | (34.32) |
Net Current Asset Value |
(50.21) | (105.78) | (80.46) | (56.30) | (95.17) | (91.08) | (77.29) | 72.99 | (327.48) | (146.54) |
EV/EBIT |
39.57 | 34.03 | 15.65 | 52.21 | 0.00 | 0.00 | 0.00 | 23.29 | 2,638.34 | 17.15 |
Capex to Sales |
1.16 | 0.61 | 0.05 | 0.13 | 0.33 | 0.10 | 0.05 | 0.04 | 0.01 | 0.04 |
Price to Operating Income |
34.92 | 28.01 | 14.87 | 44.66 | 0.00 | 0.00 | 0.00 | 21.92 | 1,828.59 | 14.25 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.03 | 1.37 | 0.89 | 1.10 | 1.08 | 0.90 | 1.38 | 1.34 | 1.43 | 1.46 |
Cash ROIC |
(38.28%) | (16.83%) | 18.07% | 3.92% | (13.63%) | (2.37%) | (6.92%) | 10.42% | 5.03% | 10.39% |
Accounts Receivable Turnover |
3.79 | 3.38 | 3.26 | 3.02 | 2.48 | 1.93 | 2.15 | 2.97 | 3.20 | 3.51 |
Accounts Payable Turnover |
17.88 | 22.52 | 11.67 | 5.38 | 6.74 | 5.88 | 5.31 | 5.50 | 6.08 | 6.31 |
Inventory Turnover |
2.47 | 2.47 | 1.87 | 1.42 | 1.60 | 1.41 | 1.48 | 1.68 | 2.02 | 2.44 |
Average Days of Payables |
25.36 | 16.76 | 44.41 | 84.42 | 47.16 | 83.32 | 77.07 | 73.76 | 66.60 | 66.93 |
Days of Inventory on Hand |
195.92 | 174.24 | 202.45 | 278.36 | 254.63 | 296.37 | 277.08 | 223.60 | 199.53 | 153.00 |
Average Receivables |
33.91 | 52.34 | 61.82 | 68.49 | 83.96 | 112.16 | 146.98 | 163.76 | 191.90 | 251.40 |
Average Payables |
2.73 | 3.51 | 6.26 | 11.75 | 12.93 | 17.11 | 26.14 | 32.99 | 41.17 | 54.12 |
Average Inventory |
19.79 | 31.96 | 39.12 | 44.33 | 54.48 | 71.25 | 93.52 | 108.28 | 123.99 | 139.92 |
Average Assets |
304.06 | 367.50 | 421.37 | 443.70 | 458.99 | 616.39 | 765.84 | 832.25 | 1,094.45 | 1,362.42 |
Average Common Equity |
164.87 | 172.20 | 186.01 | 205.03 | 204.25 | 264.80 | 323.79 | 373.22 | 418.21 | 472.20 |
Columns are period end dates